Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alicaforsen Enema in Mild to Moderate Active Ulcerative Colitis
NCT00063830Phase 2Completed
- Sponsor
- Ionis Pharmaceuticals
- Start
- Apr 2003
- Primary completion
- Oct 2004
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of alicaforsen in ulcerative colitis (UC) (5 arms), sponsored by Ionis Pharmaceuticals. Primary endpoint: Percentage reduction in Disease Activity Index at 6 weeks. Started Apr 2003; status: completed.
02
Drugs
alicaforsen
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT00063830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00063830.